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ABSTRACT 
 
   Chronic graft-versus-host disease is sometimes a severe, disabling and long-lasting complication 
of allogeneic hematopoietic stem cell transplantation. Its frequency lies between 10 and 40% of pedia-
tric graft recipients, depending on a number of risk factors. Such factors are the type, i.e. HLA-identical 
related or not, gender and age of the stem cell transplant donor, original diagnosis of the patient and, 
most importantly, the occurrence or not of a prior acute graft-verus-host disease. Chronic graft-versus-
host disease manifests itself as a collagen vascular autoimmune disease. Its treatment consists 
of immuno-modulatory and antiinfections drugs, in addition to supportive care and psycho-social 
support. Medical treatment demands a tailor-made approach and careful and prolonged surveillance. 
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INTRODUCTION 
 
   Chronic graft-versus-host disease 
(GVHD) is a possible complication of allo-
geneic hematopoietic stem cell transplan-
tation (HSCT), starting mostly between 
50 and 150 days after HSCT and fre-
quently running a severe and protracted 
course. Its appearance may either be con-
tiguous to acute GVHD (progressive form), 
after an interruption following acute GVHD 
(quiescent form), or de novo, i.e. without 
prior acute GVHD. The severity of chronic 
GVHD is graded according to clinical, 
laboratory and histologic criteria as limited 
or extensive [1]. The disability accom-
panying chronic GVHD may be scored 
according to the Karnofsky (adults) 
or Lansky (children) performance scale. 
The course on treatment may be im-
proving, stable or progressive leading 
to death of the graft recipient in 25 to 45% 
of the cases [2,3].  
   Chronic GVHD is an alloimmune disease 
with a phenotype resembling one of the 
collagen vascular (autoimmune) diseases. 
It is triggered by differences in major and 
minor histocompatibility antigens between 
the donor and the recipient, and it is effec-
tuated by T-lymphocytes of the donor. 
The spectrum of pathological lesions is 
comparable to that seen in the experi-
mental parent into F1 (non-irradiated) 
mouse model, with a major histocompa-
tibility antigen difference [4]. In minor 
histocompatibility antigen mismatched 
(lethaly irradiated) mouse models it can be 
seen that low numbers of donor T-lym-
phocytes still may produce chronic GVHD, 
whereas acute GVHD can largely be re-
duced by decreasing the number of T-lym-
phocytes in the graft [5]. Factors which 
may influence the severity of chronic 
GVHD are the number of mature T-lym-
phocytes in the graft, as illustrated by a si-
gnificantly increased risk of chronic GVHD 
after peripheral blood stem cell transplan-
tation (PBSCT) as compared with bone 
marrow transplantation (BMT) [6], and the 
occurrence of late infections after HSCT, 
e.g. CMV and VZV infections [7]. Further-
more,  there  are  indications  that  chronic 
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GVHD may in part be due to a failure in in-
ducing tolerance to (auto) antigens or to 
a relative lack of regulatory T-lympho-
cytes, as a result of damage to the thy-
mus, e.g. by the conditioning, by CSA or 
by acute GVHD [8,9]. Whether recipient 
cytokine polymorphism, e.g. for IL-6, is 
associated with the development of 
chronic GVHD [10] still needs further 
investigation.  
 
CLINICAL PRESENTATION AND PA-
THOLOGY 
 
   Chronic GVHD manifests itself as a col-
lagen vascular disease with a wide 
spectrum of tissue abnormalities [11,12]. 
Hyper- and hypopigmentation can be seen 
in the skin, and its texture can become 
scleroderma-like, sometimes resulting in 
contractures of major joints which may 
lead to severe invalidity. In cases where 
the scalp is affected hair loss frequently 
ensues. Mucous membranes, especially 
of the eyes and the oral cavity are fre-
quently involved in the process, resul- 
ting in the so-called sicca syndrome 
or Sjögren's syndrome. It frequently starts 
with white striae on the mucosa of the 
cheeks, lips and palate resembling lichen 
planus; the lesions may progress towards 
ulcers which are painful. Damage to the 
salivary glands results in dryness of the 
mouth. Eye involvement is a kerato-con-
junctivitis sicca, with a reduction in tear 
formation and complaints of grittiness and 
discomfort. Involvement of the mucous 
membranes of the esophagus and intes-
tinal tract is infrequent, and especially 
the latter must be regarded as a conse-
quence of scar formation following acute 
GVHD of the gut. Different other organs 
may take part in the process, albeit less 
frequently. Chronic GVHD of the liver 
becomes cholangiolitis and manifests itself 
as obstructive jaundice and may finally 
result in vanishing of small bile ducts. 
Obliterative bronchiolitis is rare and ma-
nifests itself as an obstructive lung dise-
ase, with dyspnoea and wheezing. It is 
often fatal because its diagnosis may 
be delayed due to its slowly progressive 
character. Also polymyositis, fasciitis and 
serositis may occur. Sometimes compli-
cations are indistinguishable from idio-
pathic autoimmune diseases and may be 
associated with mononuclear inflammatory 
lesions or the deposition of antibodies 
in tissues such as muscles and kidneys. 
Also autoimmune haemolytic anaemia and 
thrombocytopenia may be found. 
Lymphoid tissue, e.g. the spleen, may 
become hypocellular and atrophic, which 
explains the predisposition for infections 
with, e.g. pneumococci.  
   When chronic GVHD progresses, the im-
mune dysfunction also progresses, which 
leads to recurrent infections, e.g. with 
pneumoccoci and other bacteria, yeasts 
and molds, and viruses such as VZV [11]. 
The increased risk of severe infections is 
the result of both the lesions of the skin 
and mucous membranes and the hypo-
trophy of lymphoid tissue, and of the 
continued administration of immuno-
suppressive drugs to treat chronic GVHD. 
The most frequent cause of death in case 
of treatment failure are additional 
infections.  
   Histopathology does not provide much 
information. The findings confirm what 
may be expected from the clinical ab-
normalities. Only in cases of diagnostic 
doubt or when a change in treatment is 
considered, histological examination may 
give relevant additional information, e.g. 
with respect to the activity of the inflam-
mation or severity of tissue damage such 
as in the case of progressive liver 
or kidney failure.  
 
RISK FACTORS 
 
   There have been performed some large 
retrospective studies, using life-table 
analysis to study the possible relationship 
of several tens of variables for their 
association with chronic GVHD: one 
IBMTR (International Bone Marrow 
Transplant Registry)-study analyzed the 
data of 2534 evaluable BMT-recipients, 
grafted between 1982 and 1987 [13], 
another analyzed the data of a single 
center (Huddinge, Sweden) encompassing 
451 evaluable BMT-recipients, grafted 
between 1975 and 1996 [14]. Univariate 
analysis of risk factors revealed a re-
stricted number of factors significantly 
associated with chronic GVHD. Prior acute 
GVHD, increasing recipient age (or reci-
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pient age greater than 20 years), use 
of non-TCD bone marrow (for HLA-iden-
tical sibling transplants) and alloimmune 
female donors for male recipients were 
found in the IBMTR study [13],whereas 
prior acute GVHD, increasing recipient 
age, alloimmune female donors for male 
recipients and chronic myelogenous 
leukemia (CML) compared with other 
diagnoses were revealed in the Huddinge 
study [14]. Thus the pattern of major risk 
factors showed great resemblance.  
   At the Leiden Pediatrics BMT-Center we 
were able to study 407 evaluable 
transplants performed between the end 
of 1968 and 2001. These were all con-
secutive graft recipients, who survived 
for more than 50 days following trans-
plantation, and who had an engraftment 
of donor cells. Two hundred and seventy 
three children received an HLA-identical 
sibling donor transplant  (IRD) and 134 
either a haplo-identical related donor 
(ORD) or matched unrelated donor (MUD) 
transplant. The mean incidence of chronic 
GVHD was 12.8% (52 out of 407), 
of which 23 were limited and 29 exten-
sive. Patient and transplant charac-
teristics, and the frequency of chronic 
GVHD are given in Tab. 1. 
   Information obtained from the EBMT 
(European Group for Blood and Marrow 
Transplantation)-registry Working Parties 
indicated that for patients aged under 16, 
the mean frequency of chronic GVHD 
following HLA-identical sibling BMT, was 
17% in patients with AML-1st CR, 20% 
in patients with ALL-2nd CR, 26% for pa-
tients with SAA, and 37% for patients with 
adult-type CML. The Leiden Pediatrics 
population was analyzed with regard to the 
contribution of different possibly relevant 
discontinuous variables for chronic GVHD, 
using Pearson's chi-square test with 
Yates' correction. The following variables 
were found to significantly increase 
the risk of chronic GVHD: prior acute 
GVHD, donor age (donors below the age 
of 5 years gave significantly less chronic 
GVHD), type of donor (HLA-identical 
related donors (IRD) gave significantly 
less chronic GVHD than haplo-identical 
related donors (ORD) or matched unreal-
ted donors (MUD)), diagnosis (significantly 
less chronic GVHD in acute leukemia 
patients than in other diagnoses) and 
GVHD profylaxis (i.e. CSA + MTX resulted 
in less chronic GVHD than either of the 
drugs given alone). That we could not find 
an increased risk for chronic GVHD 
 
Tab. 1. Diagnosis, transplant characteristics and chronic GVHD of the Leiden Pediatrics patients. 
 
Diagnosis nrs IRD (cgvhd) 
MUD 
(cgvhd) 
ORD 
(cgvhd) cGVHD (%) 
SAA 
and BM-hypoplasia 83 64 (10) 10 (3) 9 (0) 13 (16%) 
SCID and other ID 50 14 (1) 15 (4) 21 (8) 13 (26%) 
AML, ALL, NHL,  195 157 (12) 25 (0) 13 (2) 14 (7%) 
MDS, CML 67 31 (3) 29 (6) 7 (2) 11 (16%) 
Inborn errors 12 7 (0) 5 (1) 0 1 (8%) 
Total 407 273 (26) 84 (14) 50 (12) 52 (13%) 
 
IRD: HLA-identical related donor, MUD: matched unrelated donor, ORD: other (e.g. haplo-identical) related donor 
SAA: severe aplastic anaemia, (SC) ID: (severe combined) immunodeficiency, AML: acute myelogenous leukaemia, ALL: acute 
lymphoblastic leukaemia, NHL: non-Hodgkin lymphoma, MDS: myelodysplastic syndrome, CML: (adult-type) chronic myelo-
genous leukaemia 
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following transplantation with "alloimmune" 
female donors may be due to the fact that 
243 (60%) of the donors were aged under 
16. 
 
MANAGEMENT AND OUTCOME 
 
   Chronic GVHD demands a carefully mo-
nitored and prolonged treatment, including 
a multidisciplinary approach. The mainstay 
consists of immunomodulatory treatment 
and antimicrobial profylaxis or treatment, 
if indicated. It is important to start with 
a careful initial evaluation of all tissues that 
may be affected, so as to have a starting 
point for the assessment of response 
to therapy or progression of the disease. 
It goes beyond the scope of this con-
tribution to give detailed information how 
to proceed in individual cases; only gene-
ral lines of action can be provided. 
For detailed information the reader is 
referred to the paper of Georgia Vogel-
sang [15]. The baseline immunomodu-
latory treatment consists of continuation 
of CSA, addition of corticosteroids (me-
dium dose, i.e. equivalent to 2 mg/kg/day 
prednisolon) and also of azathioprine 
especially when the course is stable or 
slowly improving. Preferably an alternate 
day corticosteroid treatment schedule 
should be instituted after a few weeks. It is 
our policy to switch to alternative therapy 
when the process has not stabilized after 
some 4 weeks, or is flaring up. The al-
ternative approach is tailormade and 
depends on the type of tissues involved. 
Possible approaches are extracorporeal 
photophoresis [16], psoralens plus ultra 
violet light (PUVA) [17], mycophenolate 
mofetil (MMF) [18] or thalidomide [19]. 
Some of these treatment modalities have 
a steroid-sparing effect. In case of flaring 
up of GVHD, a course of anti-CD25 
monoclonal antibody may suppress 
the reactivation. 
   Besides the use of immunomodulatory 
drugs, also antimicrobials are indicated 
because of the increased susceptibility 
to infections of the patient with chronic 
GVHD. It is advisable to continue anti-
microbial profylaxis with trimethoprim-
sulfamethoxazol, penicillin-V (pneumo-
cocci) and intraconazol oral solution 
(molds), as long as immunosuppressive 
drugs are given or even better, as long 
as the immune capacity of the patient is 
compromised. If indicated, i.e. in the case 
of decreased serum levels of IgG and lack 
of reaction to test-vaccinations, support 
with immunoglobulins parenteraly may be 
necessary. Re-vaccination with the usual 
set of vaccines (not with life-attenuated 
vaccines for some years after BMT) 
should be considered. 
   It seems possible to segregate patients 
into prognostic categories once chronic 
GVHD has become manifest and standard 
treatment has been started. The group 
of Vogelsang developed such a prognostic 
model and discerned some four variables 
which increased the risk of a progressive 
course c.q. a fatal outcome [3]. These 
variables were an extensive skin involve-
ment (> 50% of body surface area), a per-
sistent thrombocytopaenia (<100.000/ µl), 
a progressive form of chronic GVHD and 
a Karnofsky performance score of less 
than 50. Such a prognostic model may 
allow the identification of patients needing 
alternative treatment. The outcome 
of 52 patients with chronic GVHD, treated 
at Leiden Pediatrics, is shown in Tab. 2. 
Fifteen patients died as a consequence 
of chronic GVHD or its treatment, 9 due 
to infection, 2 as a result of progressive 
pulmonary insufficiency, 2 due to multi-
organ failure, 1 due to bronchiolitis obli-
terans and 1 as a result of progressive 
renal failure (chronic nephritis following 
haemolytic uremic syndrome). 
 
Tab. 2. Outcome of children with chronic GVHD at Leiden Pediatrics according to treatment. 
 
Treatment nrs improved stable progressed died 
no or local 4 3 1 0 1 
cortic +/- CSA 30 21 4 5 8 
cortic + aza +/- CSA 7 3 1 3 3 
"tailor-made" 11 6 2 3 3 
Total 52 33 8 11 15 
cortic: corticosteroids, CSA: cyclosporin A, aza: azathioprine 
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CONCLUSIONS 
 
   Chronic GVHD is a severe, frequently 
disabling and protracted complication 
of allogeneic HSCT. Its clinical manife-
station is comparable to that of collagen 
vascular autoimmune diseases. Some 
of the major risk factors for its onset are 
either irrelevant in the pediatric setting, i.e. 
a recipient age of above 20 years, or may 
be circumvented, e.g. the gender of the 
donor and the prevention of acute GVHD; 
others can not be circumvented e.g. 
the original diagnosis and the need to use 
another donor  than an HLA-identical 
sibling. It is important to assess the se-
verity of chronic GVHD, once present, 
as precisely as possible in order to provide 
the most appropriate therapy. A multi-
disciplinary approach using taylor-made 
treatment, and a careful evaluation of its 
result in studies including a great number 
of cases seem indicated. 
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